AKUMS DRUGS AND PHARMA L AKUMS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.akums.in

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.

Market & Price

Market Cap

₹8,030.20 Cr

Current Price

₹524.50

High / Low (52W)

₹594.00 / ₹414.05

Beta

Valuation

Stock P/E

31.44

Industry PE

37.60

Forward P/E

16.67

PEG Ratio

Book Value

₹216.55

Price to Book

2.42

P/S

1.84

EV/EBITDA

12.49

Dividend Yield

0.19%

Profitability & Returns

ROCE

10.94%

ROE

8.02%

ROA

4.80%

Profit Margin

5.85%

Op Margin

9.64%

EPS (Latest Qtr)

₹5.53

EPS (TTM)

₹16.68

Balance Sheet & Liquidity

Debt/Equity

4.73

Quick Ratio

2.26

Current Ratio

3.25

Debt

₹157.43 Cr

Total Assets

₹5,446.97 Cr

Current Assets

₹3,559.86 Cr

Working Capital

₹2,465.10 Cr

Ownership

Promoter Holding

80.17%

Chg in Prom Hold

FII / Inst Holding

13.38%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

₹6,519.84 Cr

Total Revenue (TTM)

₹4,359.02 Cr

EBITDA

₹522.02 Cr

Free Cash Flow

₹55.10 Cr

Operating Cash Flow

₹1,181.20 Cr

Shares Outstanding

₹15.31 Cr

Gross Margin

42.34%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

7.85%

Profit 5Y

39.08%

Revenue (YoY)

9.40%

Earnings (YoY)

-42.60%

PROS

Profit CAGR of 39.1% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AKUMS AKUMS DRUGS AND PHARMA L NSEPHARMA	524.50	31.44	₹8,030.20 Cr	0.19%	10.94%	8.02%	7.85%	39.08%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	1,055.55 Cr	1,024.03 Cr	1,017.53 Cr	1,159.59 Cr	1,157.87 Cr
Cost of Revenue	-	-	639.09 Cr	581.92 Cr	592.56 Cr	678.58 Cr	660.46 Cr
Gross Profit	-	-	416.46 Cr	442.12 Cr	424.97 Cr	481.01 Cr	497.41 Cr
Operating Expenses	-	-	362.55 Cr	350.07 Cr	368.36 Cr	373.80 Cr	385.80 Cr
Operating Income	-	-	53.92 Cr	92.05 Cr	56.61 Cr	107.21 Cr	111.60 Cr
EBITDA	-	-	119.67 Cr	150.83 Cr	123.44 Cr	162.96 Cr	185.23 Cr
Interest Expense	-	-	4.54 Cr	18.26 Cr	19.90 Cr	23.74 Cr	23.89 Cr
Pretax Income	-	-	75.14 Cr	95.65 Cr	65.67 Cr	99.57 Cr	121.22 Cr
Tax Provision	-	-	-74.47 Cr	30.96 Cr	22.98 Cr	31.89 Cr	39.87 Cr
Net Income	-	-	147.62 Cr	63.48 Cr	40.78 Cr	66.32 Cr	84.61 Cr
Diluted EPS	-	-	9.64	4.15	2.66	4.33	5.53

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	3,474.76 Cr	4,019.68 Cr	4,118.16 Cr	4,359.02 Cr
Cost of Revenue	-	2,307.47 Cr	2,582.22 Cr	2,433.43 Cr	2,513.52 Cr
Gross Profit	-	1,167.29 Cr	1,437.46 Cr	1,684.72 Cr	1,845.50 Cr
Operating Expenses	-	975.98 Cr	1,077.56 Cr	1,377.56 Cr	1,478.03 Cr
Operating Income	-	191.31 Cr	359.90 Cr	307.17 Cr	367.47 Cr
EBITDA	-	309.08 Cr	130.61 Cr	533.30 Cr	630.73 Cr
Interest Expense	-	45.97 Cr	50.25 Cr	34.60 Cr	94.07 Cr
Pretax Income	-	150.30 Cr	-45.28 Cr	345.25 Cr	382.10 Cr
Tax Provision	-	52.48 Cr	-46.07 Cr	1.48 Cr	125.70 Cr
Net Income	-	94.86 Cr	-4.04 Cr	338.18 Cr	255.19 Cr
Diluted EPS	-16.04	6.03	-0.28	22.60	-

Compounded Sales Growth

5 Years:	7.85%
1 Year:	9.40%

Compounded Profit Growth

5 Years:	39.08%
1 Year:	-42.60%

Stock Price Performance

1 Year:	-8.16%
6 Months:	+24.42%
3 Months:	+9.65%
1 Month:	-1.63%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	3,266.53 Cr	3,516.36 Cr	4,113.44 Cr	5,446.97 Cr
Current Assets	-	1,924.16 Cr	1,940.88 Cr	2,274.61 Cr	3,559.86 Cr
Cash & Equivalents	-	51.61 Cr	111.05 Cr	101.19 Cr	386.00 Cr
Inventory	-	729.79 Cr	630.42 Cr	680.93 Cr	755.71 Cr
Receivables	-	845.09 Cr	833.81 Cr	770.30 Cr	796.56 Cr
Total Liabilities	-	2,543.15 Cr	2,795.88 Cr	1,049.83 Cr	2,115.84 Cr
Current Liabilities	-	1,265.57 Cr	1,210.55 Cr	893.75 Cr	1,094.76 Cr
Long Term Debt	13.33 Cr	115.50 Cr	78.30 Cr	0	-
Total Debt	-	619.09 Cr	565.23 Cr	88.21 Cr	157.43 Cr
Total Equity	-	717.19 Cr	709.50 Cr	3,047.01 Cr	3,313.35 Cr
Shares Outstanding	-	15.31 Cr	15.31 Cr	15.74 Cr	15.74 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	176.63 Cr	498.26 Cr	465.20 Cr	1,181.20 Cr
Investing Cash Flow	-	-304.70 Cr	-330.42 Cr	-547.84 Cr	-930.27 Cr
Financing Cash Flow	-	124.54 Cr	-108.02 Cr	72.79 Cr	33.88 Cr
Capital Expenditure	-	-328.79 Cr	-311.41 Cr	-272.31 Cr	-230.53 Cr
Free Cash Flow	-	-152.16 Cr	186.85 Cr	192.88 Cr	950.67 Cr
Net Change in Cash	-	-3.53 Cr	59.82 Cr	-9.86 Cr	284.81 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	33.6%	35.8%	40.9%	42.3%
Operating Margin %	-	5.5%	9.0%	7.5%	8.4%
Net Margin %	-	2.7%	-0.1%	8.2%	5.9%
ROE %	-	13.2%	-0.6%	11.1%	7.7%
ROCE %	-	9.6%	15.6%	9.5%	8.4%

Shareholding Pattern

Insiders

80.17%

Institutions

13.38%

Public Float

67.46%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AKUMS

No recent headlines available.

AKUMS · Healthcare